Redhill Biopharma FY 2024 EPS $(0.00) Down From $0.01 YoY, Sales $8.04M Up From $6.53M YoY

+2.91%

RedHill Biopharma Ltd. Sponsored ADR

RDHL

0.00

Redhill Biopharma (NASDAQ: RDHL) reported quarterly losses of $(0.02) per share. This is a 300 percent decrease over earnings of $0.01 per share from the same period last year. The company reported $8.04 million in sales this quarter. This is a 23.17 percent increase over sales of $6.53 million the same period last year.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.

Recommend

Johnson & Johnson (JNJ): Assessing Valuation Following Positive Phase 3b TREMFYA® Arthritis Data and Regulatory Progress

Legend Biotech (NasdaqGS:LEGN): Assessing Valuation After Strong Results and New Philadelphia R&D Launch

Dianthus Therapeutics Joins Evercore Healthcare Conference

A Preview Of Anavex Life Sciences's Earnings

BTIG Maintains Buy on Cullinan Therapeutics, Raises Price Target to $38

Lilly Endowment Inc Reports Disposal of Eli Lilly and Company Common Shares

12 Health Care Stocks Moving In Monday's After-Market Session

Salarius Pharmaceuticals Director Arnold C. Hanish Reports Acquisition of Common Shares